REPL INVESTOR ALERT: Securities Class Action Filed Against Replimune Group, Inc. – Investors Encouraged to Contact Kirby McInerney LLP
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) common stock between October 20, 2025 and April 10, 2026, inclusive (“the Class Period”).
If you suffered a loss on your Replimune investments, you have until October 5, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff applications submitted after this deadline. If you choose to take no action, you may remain an absent class member. For more information about the lawsuit:
[CONTACT THE FIRM IF YOU SUFFERED A LOSS]
What Is This Lawsuit About? The lawsuit alleges that Replimune made materially false and/or misleading statements and failed to disclose to investors that: (i) in connection with the Biologics License Application (“BLA”) for the Company’s lead product candidate, RP1, the study design concerns previously communicated by the FDA were not addressed; (ii) the Company had submitted data from an early unplanned analysis from RP1-104, which included only 40 patients (10% of the planned enrollment of 400 patients); and (iii) as a result, RPL-0001-16 and RP1-104 had deficiencies, which were likely to cause the FDA to reject the BLA.
